Targeted screening of SiRNA directed HBV polymerase gene for effective inhibition of HBV expression

Abstract

In order to screen potential mRNA locations of P gene in which targeting siRNAs can effectively inhibit HBV expression, 5 recombinant plasmids containing 4 targeting-specific siRNA fragments and a control were prepared and transfected into 2.2.15 cells respectively. The expression levels of HBx mRNA, HBs mRNA and HBc mRNA were detected by RT-PCR. The concentrations of the hepatitis B virus antigens, including HBsAg and HBeAg harvested from the culture supernatant of transfected 2.2.15 cells, were measured by ELISA. X protein was tested by Western blot. The results showed that four siRNAs against distinct mRNA locations of HBV polymerse gene had different inhibitory effects on their targeted mRNA. The plasmid-derived psiRNA1 and psiRNA2 could effectively inhibit the transcription and translation of HBs gene, whereas the inhibitory efficiency of psiRNA3, psiRNA4 for HBe gene was much higher than that of psiRNA1 and psiRNA2. In comparison to the rest of psiRNAs in this study, psiRNA4 was the most effective to suppress the transcirption and translation of HBx. It is suggested that siRNA can be considered as a powerful therapeutic agent for reducing HBV expression. The siRNAs against HBV polymerase are effective largely depending on the location of targeted sites. To enhance inhibitory efficiency, hunting for high effective target in polymerase gene is necessary and feasible.

Keywords

RNAi / siRNA / hepatitis B virus / polymerase

References

[1] ShlomaiA., ShualY.. Inhibition of hepatitis B virus expression and replication by RAN interference. Hepatology, 2003, 37: 764-770

[2] ManciniM., DavisH., TiollasP., et al.. DNA-based immunization against the envelope proteins of the hepatitis B virus. J Biotechnol, 1996, 44: 47-57

[3] CarrenoV., CastilloI., MolinaJ., et al.. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. Hepatology, 1992, 15: 102-106

[4] LaiC. L., ChingC. K., TungA. K., et al.. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology, 1997, 25: 241-244

[5] TipplesG. A., MaM. M., FischerK. P., et al.. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology, 1996, 24: 714-717

[6] TavisJ. E., GanemD.. Evidence for activation of the hepatitis B virus polymerase by binding of its RNA template. J Virol, 1996, 70: 5741-5750

[7] RiegerA., NassalM.. Specific hepatitis B virus minus-strand DNA synthesis requires only the 5′ encapsidation signal and the 3′ proximal direct repeat DR1. J Virol, 1996, 70: 585-589

[8] GagricaS., HauserS., KolfschotenI., et al.. Inhibition of oncogenic transformation by mammalian Lin-9, a pRB-associated protein. EMBO J, 2004, 23: 4627-4638

[9] ChengJ. C., SakamotoK. M.. The emerging role of RNA interference in the design of novel therapeutics in oncology. Cell Cycle, 2004, 3: 1398-1401

[10] LeuY. W., YanP. S., FanM., et al.. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res, 2004, 6: 8184-8192

[11] MorrisseyD. V., BlanchardK., ShawnL., et al.. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology, 2005, 41: 1349-1356

[12] ZengY., YiR., CullenB. R.. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms PNAS, 2003, 17: 9779-9784

[13] KleinC., BockC. T., WedemeyerH., et al.. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology, 2003, 125: 9-18

[14] SoutschekJ., AkincA., BramlageB., et al.. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004, 432: 173-178

[15] WuH. L., HuangL. R., HuangC. C., et al.. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology, 2005, 128: 708-716

[16] ZhouX. M., LinJ. S., YiS., et al.. Establishment of a screening system for selection of siRNA target sites directed against hepatitis B virus surface gene. ABBS, 2005, 37: 310-316

[17] ZhangX. N., XiongW., WangD. J., et al.. siRNA-mediated inhibition of HBV replication and expression. World J Gastroenterol, 2004, 10: 2967-2971

[18] KhvorovaA., ReynoldsA., IayasenaS. D.. Functional siRNAs and miRNAs exhibit strand bias. Cell, 2003, 115: 209-216

[19] SchwarzD. S., HutvagnerG., DuT., et al.. Asymmetry in the assembly of the RNAi enzyme complex. Cell, 2003, 115: 199-208

[20] SilvaJ. M., SachidanandamR., HannonG. J.. Free energy lights the path toward more effective RNAi. Nat Genet, 2003, 35: 303-305

[21] LuoK. Q., ChangD. C.. The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at targeted region. Biochem Biophys Res Commun, 2004, 318: 303-310

[22] YoshinariK., MiyagishiM., TairaK.. Effects on RNAi of the tight structure, sequence and position of the target region. Nucleic Acids Res, 2004, 32: 691-699

[23] KapadiaS. B., Brideau-AndersonA., ChisariF. V.. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA, 2003, 100: 2014-2018

[24] GiladiH., KetzinelG. M., RivkinL., et al.. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther, 2003, 8(5): 769-776

[25] JacqueJ. M., TriquesK., StevensonM.. Modulation of HIV-1 replication by RNA interference. Nature, 2002, 418: 435-438